Antineoplastic drugs

Merck Announces Phase 3 KEYNOTE-826 Trial Met Dual Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Patients With Persistent, Recurrent or Metastatic Cervical Cancer

Retrieved on: 
Tuesday, June 22, 2021
Research, General Health, Pharmaceutical, Oncology, Consumer, Clinical trials, Science, Women, Biotechnology, Medical Supplies, FDA, Health, Cancer treatments, Clinical medicine, Drugs, Orphan drugs, Breakthrough therapy, Antineoplastic drugs, Cancer immunotherapy, Pembrolizumab, Merkel-cell carcinoma, Head and neck cancer, Nivolumab, Cervical Cancer, Merck, CERVICAL CANCER, MERCK

Women diagnosed with metastatic cervical cancer have a particularly poor prognosis, and there is an urgent need for new treatment options.

Key Points: 
  • Women diagnosed with metastatic cervical cancer have a particularly poor prognosis, and there is an urgent need for new treatment options.
  • KEYTRUDA, as a single agent, is indicated for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy.
  • KEYTRUDA is indicated for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma (MCC).
  • In KEYNOTE-158, KEYTRUDA was discontinued due to adverse reactions in 8% of 98 patients with recurrent or metastatic cervical cancer.

Nordic Nanovector Announces Initial Results from LYMRIT 37-05 Phase 1 Trial of Betalutin® in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Retrieved on: 
Tuesday, June 22, 2021
Non-Hodgkin lymphoma, Lymphoma, Clinical medicine, Medical specialties, Medicine, Orphan drugs, Antineoplastic drugs, Diffuse large B-cell lymphoma, Loncastuximab tesirine, Tisagenlecleucel

OSLO, Norway, June 22, 2021 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANOV) announces encouraging initial results from the LYMRIT 37-05 Phase 1 trial investigating Betalutin (177Lu lilotomab satetraxetan) in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) not eligible for stem cell transplantation.

Key Points: 
  • OSLO, Norway, June 22, 2021 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANOV) announces encouraging initial results from the LYMRIT 37-05 Phase 1 trial investigating Betalutin (177Lu lilotomab satetraxetan) in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) not eligible for stem cell transplantation.
  • The initial results from the completed Phase I study (n=16 treated with Betalutin) show that Betalutin was well tolerated, with a good safety profile consistent with all previous studies with Betalutin.
  • Peter Braun, Nordic Nanovector CEO, commented: "We continue to be very encouraged by the overall safety profile that Betalutin exhibits in even the most fragile and highly pre-treated NHL patients.
  • Raut and P. P. Chakrabarti: Management of relapsed-refractory diffuse large B cell lymphoma (2014) South Asian J.

Nordic Nanovector Announces Initial Results from LYMRIT 37-05 Phase 1 Trial of Betalutin® in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Retrieved on: 
Tuesday, June 22, 2021
Non-Hodgkin lymphoma, Lymphoma, Clinical medicine, Medical specialties, Medicine, Orphan drugs, Antineoplastic drugs, Diffuse large B-cell lymphoma, Loncastuximab tesirine, Tisagenlecleucel

OSLO, Norway, June 22, 2021 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANOV) announces encouraging initial results from the LYMRIT 37-05 Phase 1 trial investigating Betalutin (177Lu lilotomab satetraxetan) in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) not eligible for stem cell transplantation.

Key Points: 
  • OSLO, Norway, June 22, 2021 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANOV) announces encouraging initial results from the LYMRIT 37-05 Phase 1 trial investigating Betalutin (177Lu lilotomab satetraxetan) in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) not eligible for stem cell transplantation.
  • The initial results from the completed Phase I study (n=16 treated with Betalutin) show that Betalutin was well tolerated, with a good safety profile consistent with all previous studies with Betalutin.
  • Peter Braun, Nordic Nanovector CEO, commented: "We continue to be very encouraged by the overall safety profile that Betalutin exhibits in even the most fragile and highly pre-treated NHL patients.
  • Raut and P. P. Chakrabarti: Management of relapsed-refractory diffuse large B cell lymphoma (2014) South Asian J.

Nordic Nanovector ASA: Allocation of restricted stock units (RSUs) to the board of directors

Retrieved on: 
Friday, June 18, 2021
Clinical medicine, Lymphoma, Medicine, Antineoplastic drugs, Health, Drugs, Targeted therapy, Hodgkin lymphoma, CD37, Cancer

Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care.

Key Points: 
  • Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care.
  • The Company aspires to become a leader in the development of targeted therapies for haematological cancers.
  • Nordic Nanovector's lead clinical-stage candidate is Betalutin, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin's lymphoma (NHL).
  • Nordic Nanovector retains global marketing rights to Betalutin and intends to actively participate in the commercialisation of Betalutin in the US and other major markets.

Nordic Nanovector ASA: Allocation of restricted stock units (RSUs) to the board of directors

Retrieved on: 
Friday, June 18, 2021
Clinical medicine, Lymphoma, Medicine, Antineoplastic drugs, Health, Drugs, Targeted therapy, Hodgkin lymphoma, CD37, Cancer

Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care.

Key Points: 
  • Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care.
  • The Company aspires to become a leader in the development of targeted therapies for haematological cancers.
  • Nordic Nanovector's lead clinical-stage candidate is Betalutin, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin's lymphoma (NHL).
  • Nordic Nanovector retains global marketing rights to Betalutin and intends to actively participate in the commercialisation of Betalutin in the US and other major markets.

Eisai and Bristol Myers Squibb Enter Into Global Strategic Collaboration for Eisai’s MORAb-202 Antibody Drug Conjugate

Retrieved on: 
Thursday, June 17, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Life sciences, Drugs, Monoclonal antibodies, Orphan drugs, Health care, Antineoplastic drugs, Bristol Myers Squibb, Eribulin, Eisai, Squib, Bristol-Myers Squibb, Eisai Co., Ltd., Bristol Myers Squibb, MORAb-202, EISAI CO., LTD., BRISTOL MYERS SQUIBB, MORAB-202

Eisai Co., Ltd. and Bristol-Myers Squibb Company (NYSE: BMY) announced today that the companies have entered into an exclusive global strategic collaboration agreement for the co-development and co-commercialization of MORAb-202, an antibody drug conjugate (ADC).

Key Points: 
  • Eisai Co., Ltd. and Bristol-Myers Squibb Company (NYSE: BMY) announced today that the companies have entered into an exclusive global strategic collaboration agreement for the co-development and co-commercialization of MORAb-202, an antibody drug conjugate (ADC).
  • MORAb-202 is Eisais first ADC and combines Eisais in house developed anti-folate receptor alpha (FR) antibody, and Eisais anticancer agent eribulin, using an enzyme cleavable linker.
  • Bristol Myers Squibb will be solely responsible for developing and commercializing the drug in regions outside of the collaboration territories.
  • The parties will share profits, research and development and commercialization costs in the collaboration territories and Bristol Myers Squibb will pay Eisai a royalty on sales outside of the collaboration territories.

Cannabics Pharmaceuticals to launch Drug Development Programs for Prostate Cancer and Neurodegenerative & Mental Health Diseases

Retrieved on: 
Thursday, June 17, 2021
Clinical medicine, Medicine, Health, Antineoplastic drugs, Cancer, Treatment of cancer, Breast cancer, Chemotherapy, Cachexia

TEL AVIV, IsraelandBETHESDA,Maryland, June 17, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today the expansion of its research program with new drug development projects targeting Prostate Cancer, Neurodegenerative & Mental Health diseases.

Key Points: 
  • TEL AVIV, IsraelandBETHESDA,Maryland, June 17, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today the expansion of its research program with new drug development projects targeting Prostate Cancer, Neurodegenerative & Mental Health diseases.
  • The company plans to continue development of these drug candidates and continue testing with animal models while entering a drug regulatory development route for each indication.
  • The company has also recently announced a decision to enter the Melanoma and Breast Cancer markets with new drug development projects.
  • We now have four cancer treatment drug development projects for Colorectal Cancer (CRC), Melanoma, Breast Cancer and Prostate Cancer; one pre-cancer antitumor drug development project for the treatment of Adenomatous Polyps in collaboration with Digestix Bioscience Inc.; one palliative drug development project for the treatment of Cancer related Anorexia Cachexia Syndrome (CACS); and two early-stage drug discovery projects targeting Neurodegenerative and Mental Health diseases".

Worldwide Myelodysplastic Syndrome Treatment Drugs Industry to 2029 - by Drug Class and Geography - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 16, 2021
Pharmaceutical, Genetics, Health, Oncology, Myelodysplastic syndrome, MDS, Clinical medicine, Orphan drugs, Medicine, Health, Antineoplastic drugs

North America Myelodysplastic Syndrome (MDS) Treatment Drugs Market, by Drug Class, 2019 - 2029 (US$ Mn)

Key Points: 
  • North America Myelodysplastic Syndrome (MDS) Treatment Drugs Market, by Drug Class, 2019 - 2029 (US$ Mn)
    6.2.2.
  • Europe Myelodysplastic Syndrome (MDS) Treatment Drugs Market, by Drug Class, 2019 - 2029 (US$ Mn)
    6.3.2.
  • Asia Pacific Myelodysplastic Syndrome (MDS) Treatment Drugs Market, by Drug Class, 2019 - 2029 (US$ Mn)
    6.4.2.
  • Latin America Myelodysplastic Syndrome (MDS) Treatment Drugs Market, by Drug Class, 2019 - 2029 (US$ Mn)
    6.5.2.

Aprea Therapeutics Announces Phase 1/2 Trial of Eprenetapopt + Venetoclax + Azacitidine in TP53 Mutant AML Meets Complete Remission Primary Efficacy Endpoint

Retrieved on: 
Wednesday, June 16, 2021
Chemical compounds, Organic compounds, Branches of biology, Orphan drugs, Antineoplastic drugs, Lactams, Nucleosides, Triazines, Venetoclax, Azacitidine, P53

The trial met the primary efficacy endpoint of CR, which is based on a Simon 2-stage design.

Key Points: 
  • The trial met the primary efficacy endpoint of CR, which is based on a Simon 2-stage design.
  • As of the data cut, 11 patients remain on study treatment and continue to be followed for safety and efficacy.
  • We are pleased with these results from the combination of eprenetapopt with venetoclax and azacitidine in this very difficult-to-treat TP53 mutant AML population, a patient group with significant unmet medical need, said Eyal Attar, M.D., Chief Medical Officer of Aprea Therapeutics.
  • A pivotal Phase 3 clinical trial of eprenetapopt and azacitidine for frontline treatment of TP53 mutant MDS has been completed and failed to meet the primary statistical endpoint of complete remission.

Phigenix, Inc. Announces Issuance of U.S. Patent Covering Precision Medicine Diagnostic and Novel Therapeutic for Treating Drug-Resistant Breast Cancer

Retrieved on: 
Tuesday, June 15, 2021
Cancer, Clinical medicine, Medicine, Breast cancer, Cancer treatments, Oncology, Antineoplastic drugs, Metastatic breast cancer, Chemotherapy, HER2/neu

11,033,628, which is directed to methods related to the use and administration of certain PAX2 inhibitors for treating drug-resistant breast cancer.

Key Points: 
  • 11,033,628, which is directed to methods related to the use and administration of certain PAX2 inhibitors for treating drug-resistant breast cancer.
  • Drug resistance of metastatic breast cancersto first-line chemotherapies, either single or a combination ofdrugs, occurs in 30-70% of cases.
  • The technology covered in this patent has the potential to revolutionize how physicians determine the most effective course of treatment for breast cancer patients.
  • Phigenix is focused on advancing cancer disease management by utilizing molecular signature-based diagnostic tests and precision medicine-driven novel therapeutics.